– Dr. Tuyen Ong, M.D., M.B.A. appointed to Board of Directors and Dr. Jason Campagna, M.D., Ph.D. to Scientific Advisory Board –
CAMBRIDGE, Mass. – February 14, 2023 – Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing small molecule disease-modifying therapeutics that restore and enhance ABC transporter function, today announced the appointments of Tuyen Ong, M.D., M.B.A., to the Board and Directors, and Jason Campagna, M.D., Ph.D., to the Scientific Advisory Board.
“We are excited to announce the additions of Dr. Ong and Dr. Campagna to our Board of Directors and Scientific Advisory Board, respectively, as they will further support Rectify’s mission to develop a pipeline of therapeutics for patients with serious genetic and large common ABC transporter mediated diseases,” said Rajesh Devraj, Ph.D., President and Chief Executive Officer of Rectify. “Dr. Ong has a proven track record of building world class companies and a wealth of experience in the development of novel therapies. We look forward to drawing on his expertise as we advance our initial pipeline candidates into and through the clinic. Dr. Campagna has deep expertise in biliary and liver disease drug development and extensive clinical development experience. Both Dr. Ong and Dr. Campagna will be important advisors for the company as we continue to advance our ABC transporter-targeted disease-modifying therapeutics for patients. We welcome them both to Rectify.”
Dr. Tuyen Ong is currently the Chief Executive Officer at Ring Therapeutics and a CEO-Partner at Flagship Pioneering. Prior to Ring, Dr. Ong was Senior Vice President, Head of the Ophthalmology Franchise at Biogen and was Chief Development Officer at Nightstar Therapeutics until its acquisition by Biogen in 2019. Additionally, while at Nightstar, Dr. Ong was involved with the company’s NASDAQ IPO. Previously, Dr. Ong served as Chief Medical Officer at PTC Therapeutics and was responsible for progressing its pipeline of therapies for rare and genetic diseases. He also held leadership roles at Bausch and Lomb and at Pfizer, with more than 20 years’ experience in clinical and drug development. Dr. Ong was awarded his M.D. from University College London and his M.B.A. from New York University Stern School of Business.
Dr. Jason Campagna currently serves as the Chief Medical Officer at Q32 Bio Inc. Prior to this, Dr. Campagna served as Chief Medical Officer at Intercept Pharmaceuticals where he had global responsibility for major functions supporting the Primary Biliary Cholangitis (PBC) business, Non-Alcoholic Steatohepatitis (NASH) development and pipeline efforts. Before becoming Chief Medical Officer, Dr. Campagna led the Global NASH Program at Intercept, with responsibility for implementation and execution of the NASH Program, culminating in the first submitted NDA for a therapeutic intended to treat patients with NASH. Dr. Campagna has also held a number of roles of increasing responsibility at The Medicines Company, was Chief Medical Quality Officer at Cottage Health System, and has held faculty appointments at the University of Pennsylvania and Massachusetts General Hospital. Dr. Campagna obtained his Ph.D. and M.D., as well as his bachelor’s degree in Cellular and Molecular Pharmacology/Biology, from the University of Miami Miller School of Medicine.
About Rectify Pharmaceuticals, Inc. (“Rectify”)
Rectify is developing Positive Functional Modulators (PFMs), disease-modifying therapies that restore and enhance ABC transporter function to address the underlying cause of serious ABC transporter mediated diseases. Rectify is the first company to directly address the untapped therapeutic potential of the ABC transporter target class.
ATP-binding cassette (ABC) transporters are a 48-member superfamily of membrane-bound proteins that actively export a diverse range of substrates (e.g., lipids, ions, peptides, and salts) across lipid membranes. Rectify has built a breakthrough ABC transporter product platform that is enabling efficient and rapid discovery of first-in-class small molecule therapies that restore and enhance ABC transporter function for rare and common liver, biliary, eye and CNS diseases.
Rectify was founded and seeded by Atlas Venture who co-led the $100M Series A round with Omega Funds and were joined by Forbion and Longwood Fund. The company is headquartered in Cambridge, Massachusetts.
For more information, please visit www.rectifypharma.com.
Sarah Sutton/Michael Barron